Screener
Aurinia Pharmaceuticals AUPH Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Other current liabilities | 5,269 | 2,480 |
| Total current liabilities | 99,893 | 93,724 |
| Finance lease liabilities, less current portion | 43,943 | 52,322 |
| Deferred tax benefits | 23,128 | — |
| Deferred revenue, less current portion | 7,480 | 12,648 |
| Operating lease liabilities, less current portion | 2,009 | 4,900 |
| Other noncurrent liabilities | 945 | 6,662 |
| Total liabilities | 177,398 | 170,256 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's deferred tax assets?
- Aurinia Pharmaceuticals (AUPH) reported deferred tax assets of $23.13M in Q2 2026.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Aurinia Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude